Drug Profile
FB 811
Alternative Names: FB811; Glycosylated rituximab - Oneness Biotech; Rituximab biobetter - Oneness BiotechLatest Information Update: 21 Apr 2020
Price :
$50
*
At a glance
- Originator Fountain BioPharma
- Developer Oneness Biotech
- Class Antineoplastics; Biobetters; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 01 Sep 2017 Discontinued - Preclinical for Non-Hodgkin's lymphoma in Taiwan (IV)
- 04 Sep 2015 Preclinical trials in Non-Hodgkin's lymphoma in Taiwan (IV) before September 2015